European Journal of Biomedical and Pharmaceutical Sciences

METHOD FOR SIMULTANEOUS ASSESSMENT OF FIRST LINE ANTI-TUBERCULAR DRUG (RIFAMPICIN, ISONIAZID AND PYRAZINAMIDE) IN COMBINED PHARMACEUTICAL DOSAGE FORM EMPLOYING UPLC

Kishorkumar Koshe*, Umesh Maniyar, Dr. M. V. Katariya, Sushil Jaiswal, Dr. V. R. Katariya, Dr. G. S. Karva

ABSTRACT

As HPLC method is time consuming, very accurate and precise method was developed for simultaneous estimation of Rifampicin, Isoniazid and Pyrazinamide from Rifampicin, Isoniazid, Pyrazinamide and Ethambutol dosage form by UPLC. The experiment was carried out on Acquity UPLC @BEH C18, (100 mm x 2.1 mm), 1.7 μm column using the gradient composition of mixture of phosphate buffer pH 6.8 and acetonitrile in ratio of 96:4 v/v as mobile phase A and mixture of phosphate buffer pH 6.8 and acetonitrile in ratio of 45:55 v/v used as mobile phase B at flow rate 0.25 mL/min and detection wavelength 238 nm. The retention time of Rifampicin was about 3.982 min, Isoniazid was about 1.177 min and Pyrazinamide was about 1.409 min. (Figure 1). The detector response was linear in the range of 35.20 ppm to 240.00 ppm for Rifampicin, 35.20 ppm to 120.00 ppm for Isoniazide and 184.9 ppm to 645.00 ppm for Pyrazinamide.

Keywords: Development and validation of UPLC method for Rifampicin, Isoniazid and Pyrazinamid.